Piedmont Hospital’s Charles Henderson, M.D. , along with six other major liver cancer treatment centers around the country, is involved in a Phase II trial of the organic arsenic-based drug darinaparsin (Z10-101).
Darinaparsin, made by Ziopharm, is an organic compound. Administered intravenously, it causes cancer cells to die by targeting several cellular pathways essential for cell survival. Used as an adjunct to standard therapy, its goal is to prevent primary liver cancer from spreading.
Patients enrolled in the trial will receive the darinaparsin drug twice weekly for three weeks, followed by one week off, for a maximum of six months.
